Study guide
1.19 Connective Tissue & Cardiovascular Genetics
Certified Genetic Counselor CGC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics
2 Domain 1A: Clinical Information
1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review
3 Domain 1B: Human Development
1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development
4 Domain 1C: Chromosomal & Contiguous Gene Syndromes
1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)
5 Domain 1C: Hereditary Cancer Syndromes
1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition
6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions
1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework
7 Domain 2A: Pedigree & Risk Assessment
2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans
8 Domain 2B: Inheritance Principles
2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype
9 Domain 2B: Population Genetics & Variation
2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility
10 Domain 3A: Test Methodologies
3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics
11 Domain 3A: Variant Interpretation
3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework
12 Domain 3B: Testing Options
3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing
13 Domain 3C: Reproductive Risk Management
3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)
14 Domain 4A: Counseling Foundations
4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility
15 Domain 4A: Theories, Coping & Dynamics
4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics
16 Domain 4B: Communication & Education
4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making
17 Domain 5A–B: Finance & Client Resources
5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery
18 Domain 5C: Legal & Regulatory Requirements
5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing
19 Domain 5D: Professional Frameworks
5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education
20 Integration & Exam Strategy
6.1 Integrating Domains in Case-Based Practice & Exam Strategy
1.19 Connective Tissue & Cardiovascular Genetics
Key Takeaways Explain This Topic AI
Marfan syndrome (FBN1, AD) centers on aortic root aneurysm risk, ectopia lentis, and systemic features scored with revised Ghent criteria—do not diagnose from tall stature alone
Loeys-Dietz syndromes (TGF-β pathway genes) feature aggressive arterial tortuosity/aneurysms, hypertelorism, and bifid uvula/cleft palate clues distinguishing them from classic Marfan
Vascular Ehlers-Danlos syndrome (COL3A1) presents with arterial, intestinal, and uterine rupture risk—counseling urgency differs from hypermobile EDS
HCM is commonly sarcomeric (MYH7, MYBPC3); ARVC often desmosomal (e.g., PKP2); Long QT maps to channelopathy genes such as KCNQ1, KCNH2, and SCN5A
Cardiovascular genetics counseling always includes cascade relatives, activity/pregnancy risk framing, and surveillance imaging or ECG strategies matched to the condition
Last updated: August 2026
1.19 Connective Tissue & Cardiovascular Genetics
Quick Answer: Marfan = FBN1 AD aortopathy + ectopia lentis; Loeys-Dietz = TGF-β genes, bifid uvula/hypertelorism, aggressive arteries; vascular EDS = COL3A1 rupture risk; HCM ≈ MYH7/MYBPC3 ; ARVC ≈ desmosomal ( PKP2 ); LQTS ≈ KCNQ1/KCNH2/SCN5A . Cascade + imaging/ECG save lives.
Domain 1C cardiovascular items test whether you can sort overlapping aortopathy phenotypes and match cardiomyopathy/arrhythmia syndromes to gene themes —then counsel cascade testing.
Marfan Syndrome
Marfan syndrome is typically caused by heterozygous pathogenic variants in FBN1 (fibrillin-1), autosomal dominant , with substantial variable expressivity. Life-limiting risk is progressive aortic root dilation/dissection . Ocular hallmark is ectopia lentis . Skeletal features (arachnodactyly, pectus, scoliosis, hindfoot deformity) contribute to systemic scores but are not diagnostic alone.
- Domain High-yield features
- Cardiovascular Aortic root aneurysm/dissection; mitral valve prolapse
- Ocular Ectopia lentis; myopia
- Skeletal / systemic Tall stature, arm span excess, pectus, scoliosis, pneumothorax history, dural ectasia
Diagnosis framework Revised Ghent criteria combine aortic criterion, ectopia lentis, systemic score, family history, and FBN1 result
Management theme β-blockers/ARB aortopathy medical therapy per cardiology, serial echo/MRI, activity restrictions, pregnancy risk counseling
Counseling traps:
Tall athlete ≠ Marfan. Use criteria + targeted testing.
Negative FBN1 sequencing does not automatically exclude aortopathy syndromes—consider TGF-β pathway genes when Loeys-Dietz features are present.
First-degree relatives of a molecularly confirmed proband need cascade genetic testing and/or imaging surveillance if testing is declined.
Loeys-Dietz Syndrome (LDS)
Loeys-Dietz disorders are AD aortopathies/arteriopathies in the TGF-β signaling pathway , including genes such as TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3 (know the pathway theme more than every exon).
- Clue favoring LDS over classic Marfan Why it matters
- Hypertelorism, bifid uvula/cleft palate Craniofacial signature often highlighted in stems
- Arterial tortuosity; aneurysms beyond aortic root More diffuse arteriopathy
Aggressive dissection at smaller diameters (historic teaching) Surveillance and surgical thresholds may be more proactive
Clubfoot, translucent skin, easy bruising overlap Broad connective-tissue differential including vEDS
Genetic counselors should not reassure based on “Marfan-negative FBN1 ” when LDS phenotype is present—expand testing to aortopathy panels.
Vascular Ehlers-Danlos Syndrome (vEDS)
Vascular EDS is caused primarily by heterozygous pathogenic variants in COL3A1 (type III collagen), AD. It is not the same counseling conversation as hypermobile EDS.
- Feature Counseling anchor
- Catastrophic risks Arterial rupture/dissection, sigmoid colon perforation, gravid uterine rupture
Physical clues Thin translucent skin, characteristic facial features, easy bruising, clubfoot/hip dislocation history sometimes
Testing COL3A1 sequencing/deletion analysis; biochemical collagen studies historically
Management ethos Blood pressure control, emergency vascular plans, careful procedural approach, pregnancy as high-risk
Exam trap: Equating all “EDS” labels. Hypermobile EDS lacks a single reliable gene test for most patients; vascular EDS is molecularly defined and medically urgent.
Differentiating the Big Three Aortopathy/Connective Syndromes
- Feature Marfan Loeys-Dietz Vascular EDS
- Core gene theme FBN1 TGF-β pathway COL3A1
Signature clue Ectopia lentis + aortic root Bifid uvula/hypertelorism + tortuosity Hollow-organ/arterial rupture
Inheritance AD AD AD
GC priority Aortic surveillance cascade Aggressive arterial imaging cascade Emergency risk + pregnancy counseling
- Inherited Cardiomyopathies & Channelopathies
- Hypertrophic Cardiomyopathy (HCM)
Most Mendelian HCM is AD sarcomeric disease. Highest-yield genes: MYH7 and MYBPC3 (others include TNNT2, TNNI3, TPM1 ). Phenotype: left-ventricular hypertrophy unexplained by loading conditions, risk of outflow obstruction, arrhythmia, sudden cardiac death—especially relevant in adolescents/athletes.
Counseling package: cascade genetic testing when a pathogenic variant is known; otherwise clinical screening (ECG/echo) of first-degree relatives on a repeating schedule; discuss ICD decisions as cardiology-led but GC-supported risk communication.
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC/ACM)
ARVC (broader term arrhythmogenic cardiomyopathy) often involves desmosomal genes— PKP2 is the most frequently cited, with DSP, DSG2, DSC2, JUP also in the differential. Fibrofatty myocardial replacement → ventricular arrhythmias and sudden death risk; endurance athletics may worsen progression—activity counseling is part of the visit.
Long QT Syndrome (LQTS)
LQTS is a cardiac channelopathy with prolonged QTc and risk of syncope/torsades/sudden death, often triggered by genotype-specific stimuli.
- Type (classic) Gene Trigger theme (teaching)
- LQT1 KCNQ1 Exercise, swimming
- LQT2 KCNH2 Startle/auditory stimuli
- LQT3 SCN5A Sleep/rest
Management themes include β-blockers (especially LQT1/2), trigger avoidance, electrolyte vigilance, and ICD in selected high-risk patients. Cascade ECG + genetic testing of relatives is standard after a pathogenic variant is identified. Drug-induced QT prolongation counseling intersects with medication review.
Pregnancy & Activity: Cross-Cutting Counseling
- Condition Pregnancy / activity pearl
- Marfan / LDS Aortic dimension and growth rate drive pregnancy risk counseling with cardio-OB
- vEDS Pregnancy can be life-threatening (uterine rupture)—needs specialized planning
HCM / ARVC / LQTS Hemodynamic and arrhythmia risks; some sports restrictions; medication teratogenicity/compatibility review
Diagnostic Strategy for Cardiovascular Genetics Stems
Phenotype first: echo/MRI/ECG findings + dysmorphology/ocular exam.
Choose panel breadth: Marfan/LDS/vEDS aortopathy panel vs cardiomyopathy panel vs channelopathy panel.
Interpret with ACMG frameworks; VUS ≠ diagnosis.
Cascade relatives with a positive actionable variant; offer clinical surveillance if testing refused.
Document emergency plans (aortic, vascular, arrhythmia) in patient-friendly language.
These cardiovascular conditions repeatedly appear in Domain 1C and reconnect to Domain 3 predictive testing ethics when asymptomatic adolescents are offered cascade testing.